Article Text

Download PDFPDF
High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer
  1. Y. Saga*,
  2. M. Ohwada*,
  3. T. Kohno*,
  4. N. Takayashiki and
  5. M. Suzuki*
  1. * Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan
  2. Department of Pathology, Jichi Medical School, Tochigi, Japan
  1. Address correspondence and reprint request to: Mitsuaki Suzuki, M.D., Department of Obstetrics and Gynecology, Jichi Medical School, 3311, Yakushiji, Minamikawachi, Tochigi 329-0498, Japan. Email: saga{at}


Tamoxifen has been widely used in breast cancer treatment. In recent years, the occurrence of uterine malignancies in patients receiving long-term tamoxifen therapy has attracted attention. Most of these malignancies are endometrial adenocarcinomas, but low-grade endometrial stromal sarcomas have occasionally been reported. Here we report a woman who developed a high-grade endometrial stromal sarcoma after receiving postmastectomy tamoxifen therapy. The patient underwent a left mastectomy at age 45 and subsequently received oral tamoxifen for 3 years. At age 51, she was diagnosed with endometrial stromal sarcoma, for which a radical hysterectomy was performed. High-grade endometrial stromal sarcoma was diagnosed by postoperative histologic examination. Immunostaining for the estrogen receptor was negative in sarcoma cells, but positive in the residual endometrial epithelium and the nucleus of adjacent stromal cells within the tumor. The patient has now survived disease-free for 37 months after surgery.

  • estrogen receptor
  • high-grade endometrial stromal sarcoma
  • immunostaining
  • tamoxifen

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.